Cairo Pharmaceuticals results, Q1 2024
Net profit, assets, equity and cash flow for Q1 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit59.17 millionEGP · +52.5% vs the same period a year earlier
Total assets1.29 billionEGP · −2.9% vs the same period a year earlier
Shareholders' equity746 millionEGP · +1.9% vs the same period a year earlier
Operating cash flow29.8 millionEGP · +150.5% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q1 2024 was about 59.17 million EGP, up +52.5% from 38.8 million EGP in Q1 2023.
- Total assets at the end of Q1 2024 were about 1.29 billion EGP, and shareholders' equity about 746 million EGP.
- Operating cash flow for Q1 2024 was positive at 29.8 million EGP.
Key lines against the same period a year earlier
This periodQ1 2023Change
Net profit59.17 million38.8 million+52.5%
Gross profit113 million84.73 million+34.0%
Total assets1.29 billion1.33 billion−2.9%
Total liabilities546 million598 million−8.7%
Shareholders' equity746 million732 million+1.9%
Total liabilities and equity1.29 billion1.33 billion−2.9%
Operating cash flow29.8 million-59.02 million+150.5%
Investing cash flow-15.21 million-1.5 million−917.2%
Financing cash flow67.5 million29.22 million+131.0%
Net change in cash82.1 million-31.3 million+362.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy